Zacks: Brokerages Expect Isoray, Inc. (NYSE:ISR) to Announce -$0.01 EPS

Equities research analysts expect that Isoray, Inc. (NYSE:ISRGet Rating) will announce ($0.01) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Isoray’s earnings, with estimates ranging from ($0.01) to $0.00. Isoray also reported earnings per share of ($0.01) during the same quarter last year. The company is scheduled to report its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Isoray will report full year earnings of ($0.04) per share for the current year, with EPS estimates ranging from ($0.05) to ($0.03). For the next year, analysts expect that the firm will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.05) to $0.02. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Isoray.

Isoray (NYSE:ISRGet Rating) last issued its earnings results on Tuesday, February 8th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Isoray had a negative return on equity of 8.51% and a negative net margin of 52.88%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $3.06 million.

Separately, began coverage on shares of Isoray in a research report on Thursday. They set a “sell” rating for the company.

ISR opened at $0.32 on Wednesday. Isoray has a 1-year low of $0.31 and a 1-year high of $0.94. The firm has a market capitalization of $45.45 million, a P/E ratio of -6.40 and a beta of 1.02. The business’s fifty day simple moving average is $0.34.

Isoray Company Profile (Get Rating)

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Read More

Get a free copy of the Zacks research report on Isoray (ISR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with's FREE daily email newsletter.